All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Quetiapine Fumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Distriphil
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 26, 2020
Details:
Luye Pharma grants Distriphil the exclusive distribution and marketing rights for the central nervous system drugs Seroquel® (quetiapine fumarate, immediate release) and Seroquel XR® (extended release formulation) in the Philippines.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Quetiapine Fumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: CAP ALTER PHARMA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 11, 2020
Details:
Luye Pharma granted exclusive promotional rights to CAP ALTER PHARMA, INC (Alter-Pharma) for Seroquel products in 9 countries and regions including Costa Rica, Jamaica, Trinidad and Tobago, Barbados, Aruba, Curacao, Bahamas, Bermuda and The Cayman Islands.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Quetiapine Fumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Alvogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 01, 2020
Details:
Luye Pharma granted Alvogen Korea, Zuellig Pharma and DKSH exclusive distribution and marketing rights to Seroquel® (quetiapine fumarate, immediate release) and Seroquel XR® (extended release formulation) in their respective regions of South Korea, Hong Kong and Thailand.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Quetiapine Fumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Moksha8
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 14, 2020
Details:
Moksha8 subsideries, Moksha8 Brasil Distribuidora e Representação de Medicamentos Ltda and Moksha8 Farmacéutica, S. de R.L. de C.V have been granted the exclusive promotion rights for the two central nervous system (CNS) drugs: Seroquel® and Seroquel XR® in Brazil and Mexico.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Quetiapine Fumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Cipla Medpro
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 10, 2020
Details:
Luye Pharma granted the distribution and marketing rights to Cipla Medpro in South Africa and neighbouring countries on the basis of its robust business network and resources in local markets.